ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET
Company Participants
Jessica Tieszen - Associate Director of Investor Relations
Mark Johnson - Vice President of Investor Relations
Steve Davis - Chief Executive Officer
Brendan Teehan - Chief Operating Officer, Head of Commercial
Doug Williamson - Head of Research & Development
Mark Schneyer - Chief Financial Officer
Kathie Bishop - Head of Rare Diseases and External Innovation
Conference Call Participants
Tessa Romero - JPM
Charles Duncan - Cantor Fitzgerald
Marc Goodman - Leerink
Gregory Renza - RBC Capital Markets
Tazeen Ahmad - BOA
Sumant Kulkarni - Canaccord Genuity
Jason Butler - JMP
Yatin Suneja - Guggenheim
Ami Fadia - Needham and Company
Jay Olson - Oppenheimer
Operator
Good day, ladies and gentlemen and welcome to ACADIA Pharmaceuticals’ Second Quarter 2023 Financial Results Conference Call. My name is [Jeda] and I'll be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. [Operator Instructions]
I would now like to turn the presentation over to Jessica Tieszen, Associate Director of Investor Relations at ACADIA. Please proceed.
Jessica Tieszen
Thank you. Good afternoon and thank you for joining us on today's call to discuss ACADIA's second quarter 2023 financial results.
Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial who will discuss the DAYBUE launch and NUPLAZID execution. Doug Williamson, our Head of R&D will provide an update on our pipeline programs; and Mark Schneyer, our Chief Financial Officer will review the financial results. Steve will then provide some closing thoughts before we open the call up for your questions.
In addition, Kathie Bishop, our Head of Rare Diseases and External Innovation will be available for the Q&A session. We are using supplemental slides which are available on the website's Events and Presentations section.
Before we proceed, I would first like to remind you that during our call today, we'll be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements including goals, expectations, plans, prospects, growth potential, timing of events or future results are based on current information, assumptions, and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date.